PBS New Auth Codes - www.drsref.com.au

New PBS Authority Codes

www.drsref.com.au

.....

New authority codes - PBS website - below is a list of some of the most commonly prescribed authority scripts but there are 17 pages of other new codes on the PBS site - please let us know if you wish to add any other drugs to the table below. [Search]

GENERIC	BRAND	CODE	INDICATION FOR AUTHORITY
ACAMPROSATE CALCIUM	Campral	2665	For use within a comprehensive treatment program for alcohol dependence with the goal of maintaining abstinence. Note: No applications for increased maximum quantities and/or repeats will be authorised.
ALENDRONATE SODIUM	Alendro Fosamax	2645	Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less. The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated. Note: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate.
		2646	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.
ALENDRONATE SODIUM with COLECALCIFEROL	Fosamax Plus	2645	Treatment as the sole PBS-subsidised anti-resorptive agent for osteoporosis in a patient aged 70 years of age or older with a Bone Mineral Density (BMD) T-score of -3.0 or less. The date, site (femoral neck or lumbar spine) and score of the qualifying BMD measurement must be documented in the patient's medical records when treatment is initiated. Note: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate.
		2646	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body.

AMISULPRIDE	Solian	1589	Schizophrenia
ARIPIPRAZOLE	Abilify	1589	Schizophrenia.
BISOPROLOL FUMARATE	Bicor	1734	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated.

CARVEDILOL	Dilatrend Carvedilol GenRx Kredex	1734	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated;
		1735	Patients receiving this drug as a pharmaceutical benefit prior to 1 August 2002.
CLOPIDOGREL HYDROGEN SULFATE	Iscover Plavix	1719	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients with a history of symptomatic cerebrovascular ischaemic episodes while on therapy with low-dose aspirin;
		1720	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding; Note: Not for prophylaxis of DVT or peripheral arterial disease.
		1721	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs; Note: Not for prophylaxis of DVT or peripheral arterial disease.
		1722	Prevention of recurrence of myocardial infarction or unstable angina in patients with a history of symptomatic cardiac ischaemic events while on therapy with low-dose aspirin; Note: Not for prophylaxis of DVT or peripheral arterial disease.
		1723	Prevention of recurrence of myocardial infarction or unstable angina in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding; Note: Not for prophylaxis of DVT or peripheral arterial disease.
		1724	Prevention of recurrence of myocardial infarction or unstable angina in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs. Note: Not for prophylaxis of DVT or peripheral arterial disease.
DESMOPRESSIN ACETATE	Minirin	2641	Primary nocturnal enuresis in patients aged 6 years or older who are refractory to an enuresis alarm; Note: Not to be used in preference to enuresis alarms.
		2642	Primary nocturnal enuresis in patients aged 6 years or older for whom an enuresis alarm is contraindicated. The reason that an alarm is contraindicated must be documented in the patient's medical records when treatment is initiated. Note: Not to be used in preference to enuresis alarms.
		1678	Cranial diabetes insipidus
EZETIMIBE	Ezetrol	1990	Patients eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs) where treatment with an HMG CoA reductase inhibitor (statin) is unsuitable because the patient developed a clinically important product-related adverse event during treatment with a statin, and required discontinuation of all statin treatment. A clinically important product-related adverse event is defined as follows: (i) Severe myalgia (muscle symptoms without CK elevation) which is proven to be temporally associated with statin treatment; or (ii) Myositis (clinically important CK elevation, with or without muscle symptoms) demonstrated by results twice the upper limit of normal on a single reading or a rising pattern on consecutive measurements and which is unexplained by other causes; or (iii) Unexplained, persistent elevations of serum transaminases (greater than 3 times the upper limit of normal) during treatment with a statin.
		2649	coronary heart disease Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have:
		2650	diabetes mellitus Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have diabetes mellitus
		2651	peripheral vascular disease Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have peripheral vascular disease
		2652	heterozygous familial hypercholesterolaemia; Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have heterozygous familial hypercholesterolaemia
		2653	symptomatic cerebrovascular disease Treatment, in conjunction with dietary therapy and exercise, for co-administration with an HMG CoA reductase inhibitor (statin) in patients whose cholesterol levels are inadequately controlled with a statin and who have symptomatic cerebrovascular disease
EZETIMIBE	Ezetrol	2649 2650 2651 2652 2653	Inadequate control with a statin is defined as follows: (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated.
EZETIMIBE with SIMVASTATIN	Vytorin	2654	coronary heart disease Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have coronary heart disease
		2655	diabetes mellitus Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have diabetes mellitus
		2656	peripheral vascular disease Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have peripheral vascular disease
		2657	heterozygous familial hypercholesterolaemia Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have heterozygous familial hypercholesterolaemia
		2658	cerebrovascular disease which has become symptomatic Treatment, in conjunction with dietary therapy and exercise, in patients whose cholesterol levels are inadequately controlled with an HMG CoA reductase inhibitor (statin) and who have cerebrovascular disease which has become symptomatic
EZETIMIBE with SIMVASTATIN	Vytorin	2654 2655 2656 2657 2658	Inadequate control with a statin is defined as follows: (1) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs includes an initial cholesterol threshold for PBS-subsidy, a cholesterol level in excess of that threshold after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated; or (2) where the patient falls into a category for which the General Statement for Lipid-Lowering Drugs allows PBS-subsidised treatment with a statin at any cholesterol level, a cholesterol level in excess of 4 mmol per L after at least 3 months of treatment at a daily dose of 40 mg or greater of a statin, in conjunction with dietary therapy and exercise. The dose and duration of statin treatment and the cholesterol level which shows inadequate control must be documented in the patient's medical records when ezetimibe is initiated. The cholesterol level which shows inadequate control must be no more than 2 months old when ezetimibe is initiated.
EZETIMIBE with SIMVASTATIN	Vytorin	2431	homozygous familial hypercholesterolaemia Patients with homozygous familial hypercholesterolaemia who are eligible for PBS-subsidised lipid-lowering medication (according to the criteria set out in the General Statement for Lipid-Lowering Drugs).
GABAPENTIN page 7 and page 8	Gabapentin Gantin Neurontin Nupentin Gabahexal Pendine	2664	Treatment of partial epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs
LAMOTRIGINE page 9; page 10 and page 11	Lamictal Lamogine Lamitrin Elmendos Lamidus Lamotrigine Lamotrigine-DP Seaze	1426	Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs
LEVODOPA with CARBIDOPA page 11 and page 12	Sinemet CR	1257	Parkinson's disease where fluctuations in motor function are not adequately controlled by frequent dosing with conventional formulations of levodopa with decarboxylase inhibitor. [See other codes & combinations of this drug page 11 & page 12 PBS codes list]
LEVODOPA with CARBIDOPA and ENTACAPONE page 11 and page 12	Stalevo	2059	Parkinson's disease in patients being treated with levodopa�decarboxylase inhibitor combinations who are experiencing fluctuations in motor function due to end-of-dose effect;
		2060	Parkinson's disease in patients stabilised on concomitant treatment with levodopa�decarboxylase inhibitor combinations and entacapone
METOPROLOL SUCCINATE	Toprol-XL	1734	Moderate to severe heart failure in patients stabilised on conventional therapy which must include an ACE-inhibitor if tolerated.
MONTELUKAST SODIUM	Singulair	2617	children aged 2 to 5 years First-line preventer medication, as the single preventer agent for children aged 2 to 5 years with frequent intermittent or mild persistent asthma, as an alternative to sodium cromoglycate or nedocromil sodium.
		2618	children aged 6 to 14 years First-line preventer medication, as the single preventer agent for children aged 6 to 14 years with frequent intermittent or mild persistent asthma, as an alternative to sodium cromoglycate or nedocromil sodium.
OLANZAPINE	Zyprexa Zyprexa Zydis	1589	Schizophrenia
		2044	Maintenance treatment of bipolar I disorder
PIOGLITAZONE HYDROCHLORIDE	Actos	2635	Dual oral combination therapy with metformin or a sulfonylurea Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated. The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated. Note: Pioglitazone hydrochloride is not PBS-subsidised for use in combination with metformin and a sulfonylurea (triple oral therapy). Pioglitazone hydrochloride is not PBS-subsidised as monotherapy. Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances: (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or (b) red cell transfusion within the previous 3 months. A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patent's medical records
PIOGLITAZONE HYDROCHLORIDE	Actos	2638	Combination therapy with insulin Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with insulin and oral anti-diabetic agents, or insulin alone where metformin is contraindicated. The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated. Note: Pioglitazone hydrochloride is not PBS-subsidised as monotherapy. Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances: (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or (b) red cell transfusion within the previous 3 months. A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.
QUETIAPINE FUMARATE	Seroquel	1589	Schizophrenia.
RALOXIFENE HYDROCHLORIDE	Evista	2647	Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Note: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate.
RISEDRONATE SODIUM	Actonel	2646	Treatment as the sole PBS-subsidised anti-resorptive agent for established osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Note: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate.
		1392	Symptomatic Paget's disease of bone

RISPERIDONE page 14 and page 15	Risperdal Quicklet	2061	dementia Behavioural disturbances characterised by psychotic symptoms and aggression in patients with dementia where non-pharmacological methods have been unsuccessful. Caution: In placebo controlled trials in elderly patients with dementia there was a significantly higher incidence of cerebrovascular adverse events, such as stroke (including fatalities) and transient ischaemic attacks, in patients treated with risperidone compared with patients treated with placebo.
		2272	bipolar I Adjunctive therapy to mood stabilisers for up to 6 months, of an episode of acute mania associated with bipolar I disorder.
		1589	Schizophrenia
		2598	autism- paed. behaviour disturbances, severe; Treatment under the supervision of a paediatrician or psychiatrist, in combination with non-pharmacological measures, of severe behavioural disturbances in a child or adolescent aged less than 18 years with autism. Behaviour disturbances are defined as severe aggression and injuries to self or others whesevere behavioural disturbances in a child or adolescent aged less than 18 years with autismre non-pharmacological methods alone have been unsuccessful.. The diagnosis of autism must be made based on the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) or ICD-10 international classification of mental and behavioural disorders.
ROSIGLITAZONE MALEATE page 15 and page 16	Avandia Avandamet	2633	Type 2 diabetes in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with metformin and where a sulfonylurea is contraindicated or not tolerated. The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated. Note: Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances: (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or (b) red cell transfusion within the previous 3 months. A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.
ROSIGLITAZONE MALEATE page 15 and page 16	Avandia Avandamet	2634	Type 2 diabetes, in combination with a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with maximally tolerated doses of metformin and a sulfonylurea. The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated. Note: Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances: (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or (b) red cell transfusion within the previous 3 months. A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.
ROSIGLITAZONE MALEATE page 15 and page 16	Avandia	2635	Dual oral combination therapy with metformin or a sulfonylurea Type 2 diabetes, in combination with either metformin or a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with either metformin or a sulfonylurea and where a combination of metformin and a sulfonylurea is contraindicated or not tolerated. The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated. Note: Rosiglitazone maleate is not PBS-subsidised as monotherapy. Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances: (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or (b) red cell transfusion within the previous 3 months. A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.
ROSIGLITAZONE MALEATE page 15 and page 16	Avandia	2638	Combination therapy with insulin Type 2 diabetes, in combination with insulin, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with insulin and oral anti-diabetic agents, or insulin alone where metformin is contraindicated. The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated. Note: Rosiglitazone maleate is not PBS-subsidised as monotherapy. Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances: (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or (b) red cell transfusion within the previous 3 months. A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.
ROSIGLITAZONE MALEATE page 15 and page 16	Avandia	2648	Triple oral combination therapy with metformin and a sulfonylurea Type 2 diabetes, in combination with metformin and a sulfonylurea, in a patient whose HbA1c is greater than 7% prior to initiation of a thiazolidinedione (glitazone) despite treatment with maximally tolerated doses of metformin and a sulfonylurea. The date and level of the HbA1c must be documented in the patient's medical records at the time glitazone treatment is initiated. The HbA1c must be no more than 4 months old at the time glitazone treatment is initiated. Note: Rosiglitazone maleate is not PBS-subsidised as monotherapy. Blood glucose monitoring may be used as an alternative assessment to HbA1c levels in the following circumstances: (a) clinical conditions with reduced red blood cell survival, including haemolytic anaemias and haemoglobinopathies; and/or (b) red cell transfusion within the previous 3 months. A patient in these circumstances will be eligible for treatment where blood glucose monitoring over a 2 week period shows blood glucose levels greater than 10 mmol per L in more than 20% of tests. The results of this blood glucose monitoring, which must be no more than 4 months old at the time of initiation of glitazone therapy, must be documented in the patient's medical records.
STRONTIUM RANELATE	Protos	2647	Treatment as the sole PBS-subsidised anti-resorptive agent for established post-menopausal osteoporosis in patients with fracture due to minimal trauma. The fracture must have been demonstrated radiologically and the year of plain x-ray or CT-scan or MRI scan must be documented in the patient's medical records when treatment is initiated. A vertebral fracture is defined as a 20% or greater reduction in height of the anterior or mid portion of a vertebral body relative to the posterior height of that body, or, a 20% or greater reduction in any of these heights compared to the vertebral body above or below the affected vertebral body. Note: Anti-resorptive agents in established osteoporosis include alendronate sodium, risedronate sodium, disodium etidronate, raloxifene hydrochloride and strontium ranelate.
SUMATRIPTAN	Imigran Nasal spray	2663	Migraine attacks in patients receiving, or who have failed a reasonable trial of, prophylactic medication and where attacks in the past have usually failed to respond to oral therapy with ergotamine and other appropriate agents, or in whom these agents are contraindicated. Note: No applications for increased maximum quantities and/or repeats will be authorised.
SUMATRIPTAN SUCCINATE	Imigran FDT Imigran Sumatab Suvalan	2663	Migraine attacks in patients receiving, or who have failed a reasonable trial of, prophylactic medication and where attacks in the past have usually failed to respond to oral therapy with ergotamine and other appropriate agents, or in whom these agents are contraindicated. Note: No applications for increased maximum quantities and/or repeats will be authorised.
TICLOPIDINE HYDROCHLORIDE	Ticlopidine Hexal Ticlid Tilodene	1719	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients with a history of symptomatic cerebrovascular ischaemic episodes while on therapy with low-dose aspirin;
		1720	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where low-dose aspirin poses an unacceptable risk of gastrointestinal bleeding;
		1721	Prevention of recurrence of ischaemic stroke or transient cerebral ischaemic events in patients where there is a history of anaphylaxis, urticaria or asthma within 4 hours of ingestion of aspirin, other salicylates, or NSAIDs;
		1260	Patients established on this drug as a pharmaceutical benefit prior to 1 November 1999.
VIGABATRIN	Sabril	1426	Treatment of epileptic seizures which are not controlled satisfactorily by other anti-epileptic drugs.
ZIPRASIDONE HYDROCHLORIDE	Zeldox	1589	Schizophrenia

Do you know of information which should be included on this page?
If so then click here. Your comments are most welcome.